

Name of the Issuer:		JFL Life Sciences Limited	Last updated on	14 th July, 2025
1	Type of Issue (IPO / FPO)		IPO	
2	Issue Size (Rs. crore)* - Fresh Issue Size (Rs. crore) <i>*Source: Prospectus dated August 11, 2022 and Final Post issue report dated September 10, 2022</i>		18.16	
3	Grade of issue along with name of the rating agency Name Grade		Not Applicable Not Applicable	
4	Subscription Level (Number of times) <i>Source: Final Post issue report dated September 10, 2022</i> <i>*The above figure is after technical rejections</i>		6.01*	
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges			
	Particulars		%	
	(i) allotment in the issue ⁽¹⁾		0.00%	
	(ii) at the end of 1st Quarter immediately after the listing ⁽²⁾		0.00%	
	(iii) at the end of 1st FY (March 31, 2023) ⁽²⁾		0.00%	
	(iv) at the end of 2nd FY (March 31, 2024) (2)		0.00%	
	(v) at the end of 3rd FY (March 31, 2025)		0.00%	
	<i>*QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.</i>			
	<i>(1) Source: Basis of Allotment</i>			
	<i>(2) Source: Shareholding pattern as available on NSE</i>			
6	Financials of the issuer			
	Parameters	1st FY (March 31, 2023) ⁽¹⁾	2nd FY (March 31, 2024)	(In Rs. crore) 3rd FY (March 31, 2025)
	Income from operations	42.83	46.55	82.04
	Net Profit for the period	2.80	3.30	4.15
	Paid-up equity share capital	11.00	11.00	32.99
	Reserves excluding revaluation reserves	21.27	24.58	6.46
	<i>*Financials not disclosed as reporting for the relevant fiscal year has not been completed.</i>			
	<i>(1) Source: Annual Report of the Company for relevant FY.</i>			
7	Trading Status in the scrip of the issuer Company's Equity Shares are listed on National Stock Exchange of India Limited (SME Platform) The Shares have not been suspended or delisted.			
	Particulars		Status	
	(i) at the end of 1st FY (March 31, 2023)		Frequently Traded	
	(ii) at the end of 2nd FY (March 31, 2024)		Frequently Traded	
	(iii) at the end of 3rd FY (March 31, 2025)		Frequently Traded	
	<i>*Trading status not disclosed as the relevant fiscal year has not been completed.</i>			
8	Change in Directors of issuer from the disclosures in the offer document			
	Particulars	Name of the Director	Appointed / Resigned	
	(i) at the end of 1st FY (March 31, 2023)	Pratima Singh	Resignation	
		Malvika Jagani	Appointment	
	(ii) at the end of 2nd FY (March 31, 2024)	Mr. BHAUMIK SANJAYKUMAR SHAH	Resignation	
		Manishkumar Jasvantal Patel	Appointment	
	(iii) at the end of 3rd FY (March 31, 2025)*	Not applicable	Not applicable	
	Source: Stock Exchange Filings			
	* Changes in Directors of Issuer not updated as the relevant financial years have not been completed			

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document

(Rs. crore)

Objects of the Fresh Issue	Amount
Repayment of Secured and Unsecured Loan	7.50
To meet Working Capital requirements	6.00
General Corporate Purpose	4.26
Total	17.76

Source: Prospectus dated August 11, 2022

(ii) Actual utilization

(Rs. crore)

Objects of the Fresh Issue	Amount
Repayment of Secured and Unsecured Loan	7.50
To meet Working Capital requirements	6.00
General Corporate Purpose	4.26
Total	17.76

Source: NSE Filing

(iii) Reasons for deviation, if any

Not applicable

11 Comments of monitoring agency

(a) Comments on use of funds

(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document

(c) Any other reservations expressed by the monitoring agency about the end use of funds

Not Applicable, since Issue size is less than Rs. 100 crores

12 Pricing Data

Issue Price (Rs.):

61

Designated Stock Exchange:

NSE

Listing Date:

08-Sep-22

Price parameters	At close of listing day (Sept 08, 2022)	At close of 30th calendar day from listing day (Oct 07, 2022) ⁽¹⁾	At close of 90th calendar day from listing day (Dec 06, 2022) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2023) ⁽³⁾		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE	66.50	43.30	37.50	33.00	52.50	30.10
NIFTY50	17,633.35	17,314.65	16,942.75	17,339.75	18,667.00	15,163.40
SECTORAL INDEX (NIFTY Healthcare)	8052.60	8296.05	8278.10	7621.55	7661.40	7578.85
Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2024)			As at the end of 3rd FY after the listing of the issue (March 31, 2025)		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE	40.50	56.00	34.70	17.45	75.1	15.95
NIFTY50*	22,163.60	22,526.60	17,312.75	23585.03	26055.72	22140.81
SECTORAL INDEX (NIFTY Healthcare)	12059.30	14971.80	9198.30	13681.30	15075.35	11625.45

*Being index of NSE, the designated stock exchange

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on intra day prices

(4) In case of any reporting day falling on a holiday, previous trading day prices has been disclosed.

13 Basis for Issue Price

Accounting ratio	Name of company	As disclosed in the offer document (See (9)(K) Schedule VI of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018)	At the end of 1 st FY March 31, 2023*	At the end of 1 st FY March 31, 2024*	At the end of 2 nd FY March 31, 2025
EPS	Issuer:	3.7	2.	3.0	1.26
	Peer Group: Zenith Health Care Limited	0.05	0.0	0.03	0.013
	Vaishali Pharma Limited	3.8	6.2	0.6	0.31
	Industry Avg:	1.93	3.1	0.32	0.47
P/E	Issuer:	16.1	11.3	13.4	13.84
	Peer Group: Zenith Health Care Limited	102.7	3.9	0.8	321.54
	Vaishali Pharma Limited	23.3	23.	23.	40.58
	Industry Avg:	63.0	13.6	11.9	123.29
RoNW	Issuer:	7.18%	13%	9.30%	10.53 %
	Peer Group: Zenith Health Care Limited	4.54%	1.07%	2.77%	0.92%
	Vaishali Pharma Limited	17.95%	16.29%	15.41%	1.26%
	Industry Avg:	9.89%	8.6	9.0	4.24%
NAV per share based on balance sheet	Issuer:	138.2	29.3	32.3	119.58
	Peer Group: Zenith Health Care Limited	1.3	0.6	1.3	1.38
	Vaishali Pharma Limited	24.9	18.4	39.9	4.98
	Industry Avg:	13.1	9.5	20.6	41.98/

Notes:

(1) Sourced from Prospectus dated August 11, 2022.

* Source: Stock Exchange Filing

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

(i) Earnings per Equity Share are computed in accordance with Accounting Standard 20 "earnings per Share" notified by the Companies (Accounting Standards) Rules, 2006.

(ii) NAV per share - Net asset value per Equity Share represents net worth as at the end of the Fiscal divided by the number of Equity Shares outstanding at the end of the Fiscal

(iii) P/E - Closing Market Price as of relevant fiscal year end / Basic EPS for the Fiscal

(iv) RoNW - Return on net worth (%) is net profit attributable to equity shareholders divided by net worth for the Fiscal

14. Other material information:-

4-Nov-22	Jfl Life Sciences Limited has informed the Exchange about resignation of PRATIMA SINGH as Compliance Officer of the company w.e.f. 04-Nov-2022
12-Nov-22	Jfl Life Sciences Limited has informed the Exchange about appointment of MALVIKA JAGANI as Company Secretary of the company w.e.f. 12-Nov-2022
12-Nov-22	It is hereby informed that there is no deviation in the utilization of Issue proceeds of IPO
12-Nov-22	Jfl Life Sciences Limited has informed the Exchange about appointment of PRASHANT PATEL as Internal Auditor of the company w.e.f. 12-Nov-2022
9-Dec-22	The Exchange has sought clarification from Jfl Life Sciences Limited with respect to Financial Results dated 12-Nov-2022 for the period Sep, 2022On the basis of aforesaid disclosure, the Listed entity is required to clarify the following:1. Standalone: Segment Reporting-Not foundThe response of the company is awaited
02-Aug-24	The Board Considered and approved the proposal of raising of funds by the Company through Right issue or Further issue or Preferential issue of Equity Shares or any combination thereof sum upto sum not exceeding Rs. 50.00 Crore
02-Aug-24	Jfl Life Sciences Limited has informed the Exchange about issuance of bonus shares
02-Aug-24	Jfl Life Sciences Limited has informed the Exchange about the Board Recommendation of final dividend of 2.5 % i.e., Rs. 0.25 per equity share for the Financial Year ended March 31, 2024, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company to be held for the Financial Year 2023-24
31-Aug-24	Jfl Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2024
05-Nov-24	JFL LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 14-Nov-2024 to inter-alia consider and approve the Audited Financial results of the Company for the Half Yearly ended September 2024
14-Nov-24	Jfl Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2024.
24-Jan-25	Jfl Life Sciences Limited has informed the Exchange regarding Cessation of Ms Malvika Jagani as Company Secretary & Compliance Officer of the company w.e.f. January 24, 2025
19-Mar-25	JFL LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 27-Mar-2025 to consider Fund raising
27-Mar-25	Jfl Life Sciences Limited has informed the Exchange regarding Appointment of Ms HIRAL CHUDASAMA as Company Secretary & Compliance Officer of the company w.e.f. March 28, 2025
27-Mar-25	The Board Considered and approved, raising of Funds through issuance of Equity shares of value upto Rs. 49,50,00,000/- (Rupees Forty Nine Crores Fifty Lakhs) by way of a rights issue to the eligible equity Shareholders of the Company on Right Issue basis, on such terms and at such price and ratio as may be decided by the board at a later date, as on record date (to be notified subsequently).
03-Apr-25	JFL LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 08-Apr-2025 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended December 2025
08-Apr-25	appointed Ms. Amita Pragada as an Additional Independent Director with effect from April 08, 2025

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by GYR Capital Advisors Private Limited ("GYR") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges"), as applicable, from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, GYR does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither GYR nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement.